Alpha Cognition Inc (TSE:ACOG) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alpha Cognition Inc. has released promising interim preclinical data for its drug ALPHA-1062, aimed at treating mild traumatic brain injuries caused by repetitive blast trauma, a common military injury. The study, supported by the US Department of Defense, shows that ALPHA-1062 reduces neuroinflammation and neuropathology in the brain. This progress signals a potential breakthrough in treating brain injuries related to military service.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.